Clinical trials: Advanced Solid Malignant Tumor
Neoplasms, Malignant
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors
Primary Objective: To determine the maximum tolerated dose based on the incidence of dose limiting toxicity and the maximum administered dose of ombrabulin in combination with docetaxel and cisplatin administered every 3 weeks in…
- Trial name
- NCT01095302
- Testing
- OMBRABULIN (AVE8062), cisplatin, docetaxel
- Where
- 3 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Sanofi
Solid Tumor
A Study of EMD525797 in Solid Tumor Patients in Japan
The primary objectives are to assess the safety and tolerability of single and repeated doses of EMD525797, and characterize Pharmacokinetics (PK).
- Trial name
- NCT01327313
- Testing
- EMD525797
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Head and Neck Squamous Cell Carcinoma, Solid Tumor
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is an open, multicenter, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic…
- Trial name
- NCT07232524
- Testing
- BL-M24D1
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumor
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
This study consists of Part A for monotherapy and Part B for combination therapy to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 in patients with advanced solid tumors.
- Trial name
- NCT05204862
- Testing
- TU2218, Anti-PD-1 antibody
- Where
- 3 sites in United States, South Korea
- Volunteers
- 240 people
- Sponsor
- TiumBio Co., Ltd.
Solid Tumor, Adult
A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)
This is an open label Phase 1a/1b study in patients who have advanced solid cancer tumours. Patients will receive MTL-CEBPA (an experimental drug) in combination with pembrolizumab (a drug which has been given approval for use…
- Trial name
- TIMEPOINT (NCT04105335)
- Testing
- MTL-CEBPA, Pembrolizumab
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Mina Alpha Limited
Solid Tumor
A Study of WX390 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to evaluate the efficacy and safety of WX390 in patients with advanced solid tumors. The main questions it aims to answer are: PFS, OS, DoR at week 48; antitumor effects at week 24 and week 48.
- Trial name
- NCT06117540
- Testing
- WX390
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
Advanced Solid Tumor
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
This study is a phase I/II study of single drug TJ004309 and Toripalimab combine treatment for Advanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension.
- Trial name
- NCT04322006
- Testing
- TJ004309, Toripalimab
- Where
- 23 sites in China
- Volunteers
- 225 people
- Sponsor
- TJ Biopharma Co., Ltd.
Advanced Solid Tumor
A Study of MSB0254 Injection in Advanced Solid Tumors
This study was an open, multi-dose dose escalation phase I clinical study to evaluate the safety, tolerability and PK characteristics of MSB0254 in patients with locally advanced or metastatic solid tumors, and to preliminarily…
- Trial name
- NCT04381325
- Testing
- MSB0254 Injection
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Solid Tumor Cancer, Lymphoma
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
SB-485232 will be administered as five daily intravenous (IV) infusions repeated every 28 days in adult subjects with advanced solid tumors or lymphomas.
- Trial name
- NCT00085904
- Testing
- SB-485232
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Cancer
A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors
The primary purpose of this study is to evaluate the effect of food on oral LBH589 in adult patients with advanced solid tumors.
- Trial name
- NCT00570284
- Testing
- LBH589
- Where
- 9 sites in United States, Sweden and 1 more
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
GenSci143 in Participants With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors
- Trial name
- NCT07252414
- Testing
- GenSci143 for injection
- Where
- 13 sites in United States, China
- Volunteers
- 180 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Advanced Solid Tumor
Study in Advanced Solid Tumor Patients
The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE).
- Trial name
- NCT07300943
- Testing
- CLIO-8221
- Where
- 11 sites in United States, Australia
- Volunteers
- 306 people
- Sponsor
- Callio Therapeutics
Advanced Solid Tumor
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced solid tumors.
- Trial name
- NCT06258408
- Testing
- BB102 tablet
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Broadenbio Ltd., Co.
Solid Tumor, Adult
A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors
BY101921 is a novel small molecule, being developed as a PARP7 inhibitor which acts on the PARP7 catalytic subunit, for the treatment of solid tumors.
- Trial name
- NCT06433726
- Testing
- BY101921 tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chengdu Baiyu Pharmaceutical Co., Ltd.
Tumor
To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors
The primary objective of this study was to assess the effect of cytochrome P450 3A4 enzyme (CYP3A4) induction by rifampicin on the pharmacokinetics (PK) of eribulin mesylate following intravenous (IV) administration in…
- Trial name
- NCT03002493
- Testing
- Eribulin mesylate, Rifampicin
- Where
- 2 sites in Netherlands
- Volunteers
- 14 people
- Sponsor
- Eisai Limited
Solid Tumor, Adult
Study of FCN-437c in Patients With Advanced Solid Tumors
This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.
- Trial name
- FCN-437c (NCT03951116)
- Testing
- FCN-437
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Fochon Pharmaceuticals, Ltd.
Cancer, Neoplasms
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
- Conditions
- Cancer, Neoplasms, Neoplasms, Breast, Tumor
- Trial name
- NCT06819215
- Testing
- VB15010
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Melanoma, Non Small Cell Lung Cancer
Dabrafenib and/or Trametinib Rollover Study
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
- Trial name
- NCT03340506
- Testing
- dabrafenib, trametinib
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Small Cell Lung Cancer, Non-small Cell Lung Cancer
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
This amended expansion phase of the protocol is to further the experience at a dose level of 150 mg CPT eq/m2 in patients with Stage IV non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and to test for…
- Trial name
- NCT00455052
- Testing
- XMT-1001
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mersana Therapeutics
Solid Tumors
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
This is a phase I clinical study. All subjects are patients with advanced solid tumors. The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor…
- Trial name
- NCT07274085
- Testing
- HDM2017
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.